Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Resmed Inc (NY: RMD )

242.51 -3.27 (-1.33%)
Official Closing Price Updated: 7:00 PM EST, Dec 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Resmed Inc

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Should you consider RESMED INC (NYSE:RMD) for quality investing?
RESMED INC (NYSE:RMD) may be suited for quality investing, we'll explore why in this article. 
Via Chartmill
ResMed Is 80 And 80: Hits 80-Plus Relative Strength Rating After Rising 80% In A Year
ResMed also boasts a superb 96 EPS Rating out of 99, putting it in the top 4% of all companies for recent and long-term profit growth. 
Via Investor's Business Daily
Why Quality-Oriented Investors Should Consider NYSE:RMD.
Exploring RESMED INC (NYSE:RMD)'s quality characteristics. 
Via Chartmill
P/E Ratio Insights for ResMed
Via Benzinga
Stock Market Mixed But Nasdaq Hits Record High As Tesla Leads Earnings Winners: Weekly Review
The major indexes were mixed for the week. 
Via Investor's Business Daily
Cracking The Code: Understanding Analyst Reviews For ResMed
Via Benzinga
A Peek at ResMed's Future Earnings
Via Benzinga
Is RESMED INC (NYSE:RMD) suited for quality investing?
Analyzing the Quality Characteristics of RESMED INC (NYSE:RMD). 
Via Chartmill
Tech Stocks Rally As Investors Await Magnificent 7 Earnings; Dollar Eyes Fourth Straight Positive Week: What's Driving Markets Friday?
Stocks are ending the week on a high note, with tech leading the charge as investors position ahead of next week’s pivotal earnings releases from five of the “Magnificent Seven” stocks. 
Via Benzinga
Sleep Apnea Device Maker ResMed Is A Durable MedTech, With Positive Fundamentals, Says Analyst
ResMed reports Q1 2025 adjusted EPS of $2.20, up 34%, beating estimates. Revenue reached $1.22 billion, up 11%, driven by demand growth. 
Via Benzinga
My 3 Favorite Stocks to Buy Right Now
Here are three attractive stocks to buy that will give you a healthy mix of growth and dividends. 
Via The Motley Fool
Expert Outlook: ResMed Through The Eyes Of 7 Analysts
Via Benzinga
Reasonable growth and debt and a high ROIC for RESMED INC (NYSE:RMD).
Why NYSE:RMD Stands Out as a Quality Stock. 
Via Chartmill
How Is The Market Feeling About ResMed?
Via Benzinga
Obesity Drugs-Tied ResMed Edges Higher On Quarterly Beat
The company beat fiscal first-quarter expectations. Shares are forming a flat base. 
Via Investor's Business Daily
Wall Street's Top 10 Stock Calls This Week - Saturday, Sept. 21
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Sept. 16-20, 2024. 
Via Talk Markets
Why ResMed Stock Tumbled by 5% Today
A looming threat from a very powerful rival could significantly dampen a key business for the company. 
Via The Motley Fool
Stocks Edge Lower As Fed Rate Decision Looms, Treasury Yields Rise As Odds Improve For Smaller Cut: What's Driving Markets Wednesday?
Wall Street is jittery hours before the highly anticipated Federal Open Market Committee (FOMC) meeting, with all major indices posting modest losses by midday in New York. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Here's How Much You Would Have Made Owning ResMed Stock In The Last 15 Years
Via Benzinga
Why Quality-Oriented Investors Should Consider NYSE:RMD.
Exploring RESMED INC (NYSE:RMD)'s quality characteristics. 
Via Chartmill
NYSE:RMD may be ready to breakout.
There are signs that NYSE:RMD may be ready to breakout. 
Via Chartmill
Uncovering Dividend Opportunities with NYSE:RMD.
Is RESMED INC (NYSE:RMD) a Good Fit for Dividend Investing? 
Via Chartmill
A Glimpse Into The Expert Outlook On ResMed Through 6 Analysts
Via Benzinga
$1000 Invested In ResMed 10 Years Ago Would Be Worth This Much Today
Via Benzinga
RxSight Stock Sees Relative Strength Rating Rise To 91
On Monday, RxSight stock earned a positive adjustment to its Relative Strength (RS) Rating, from 88 to 91. 
Via Investor's Business Daily
If You Invested $1000 In This Stock 15 Years Ago, You Would Have $9,500 Today
Via Benzinga
DoorDash And Exact Sciences Are Among Top 10 Large Cap Gainers Last Week (July 28-Aug 3): Are The Others In Your Portfolio?
Top 10 stocks with highest gains last week, including Exact Sciences, Alnylam Pharmaceuticals, Resmed, Coca-Cola Consolidated, DexCom, Sprouts Farmers Market, UL Solutions, Labcorp Holdings, C.H.... 
Via Benzinga
ResMed's Options Frenzy: What You Need to Know
Via Benzinga
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $16,000 Today
Via Benzinga
ResMed Earnings Reflect Increased Demand For Sleep Devices, Performance Indicates Positive Dynamics, Opportunities
ResMed reported Q4 2024 revenue of $1.22 billion, driven by strong demand for sleep devices and software services. Gross margin improved significantly due to reduced costs and higher selling prices.... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.